Elmelech Idan
SEC insider (Form 3/4/5 filer). CIK 0002058437. COO & Principal Financial Ofcr at BridgeBio Oncology Therapeutics, Inc. (BBOT). 3 reported Form 4/5 transactions since Sep 2024; latest on Oct 1, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Elmelech Idan has filed insider reports for
- BridgeBio Oncology Therapeutics, Inc. (BBOT): Officer, COO & Principal Financial Ofcr
Elmelech Idan
CIK: 0002058437
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (33.3%)
Compensation grants
Other (G, F, J, C, D, …)2 (66.7%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BBOT
BridgeBio Oncology Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Oct 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Tax PaymentDirect343 shares at avg. $3.94$1K - Jul 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Tax PaymentDirect343 shares at avg. $7.80$3K - May 10, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
758.2K shares-
1-3 of 3 transactions